Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2086 to 2100 of 7682 results

  1. Bismuth subcitrate potassium–metronidazole–tetracycline hydrochloride with omeprazole for treating Helicobacter pylori and preventing peptic ulcer relapse TS ID 11900

      Status ...

    Health technology evaluations
    Topic selection

  2. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]

    Awaiting development [GID-TA11341] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

    Medical technologies guidance
    Published
    25 July 2011
    View recommendations

    Sections for MTG6

  4. Spinal instrumentation with robot assisted navigation

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  5. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years TSID 12002

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis TS ID 11895

      Status ...

    Technology appraisal guidance
    Topic selection

  7. The MIST Therapy system for the promotion of wound healing (MTG5)

    Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.

    Medical technologies guidance
    Published
    25 July 2011
    View recommendations

    Sections for MTG5

  8. moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment (MTG2)

    Evidence-based recommendations on moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment.

    Medical technologies guidance
    Last updated
    7 August 2017
    View recommendations

    Sections for MTG2

  9. Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]

    Awaiting development [GID-TA10718] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

    Awaiting development [GID-TA10717] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Digital platforms for community based self-management of mild to moderate osteoarthritis and joint pain

    Awaiting development [GID-MT610] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  12. Secukinumab biosimilar for treating plaque psoriasis TSID 11992

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995

    Awaiting development [GID-TA11525] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996

    Awaiting development [GID-TA11526] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Zavegepant for treating acute migraine TSID 11998

    Awaiting development [GID-TA11527] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development